{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:57:21Z","timestamp":1709859441206},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11864-018-0594-1","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T23:54:51Z","timestamp":1541462091000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment"],"prefix":"10.1007","volume":"19","author":[{"given":"Daniele","family":"Grimaldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"594_CR1","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"594_CR2","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"F Massimo","year":"2009","unstructured":"Massimo F, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"594_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"issue":"5","key":"594_CR4","first-page":"88","volume":"4","author":"NO Nagham","year":"2016","unstructured":"Nagham NO, Abolela MS, Abdelgawad MI, Ibrahim A, Mourad AF, Rezk K. Diagnostic Utility of 18F-FDG PECT\/CT in Assessment of Post-therapy Remission or Relapse of Lymphoma. Cancer Res Treat. 2016;4(5):88\u201395.","journal-title":"Cancer Res Treat"},{"key":"594_CR5","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1:e17\u201327.","journal-title":"Lancet Haematol"},{"key":"594_CR6","doi-asserted-by":"crossref","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H. et al. Impact of [18F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012.","DOI":"10.1200\/JCO.2012.43.0934"},{"key":"594_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger A, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111\u201322.","journal-title":"Lancet Oncol"},{"key":"594_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/hon.2437_85","volume":"35","author":"S Huet","year":"2017","unstructured":"Huet S, Szafer- Glusman E, Xerri L, Bolen C, Punnoose C, Tonon L, et al. Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial. Hematol Oncol. 2017;35:96\u20137.","journal-title":"Hematol Oncol"},{"key":"594_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19:549\u201361.","journal-title":"Lancet Oncol"},{"key":"594_CR10","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/sj.leu.2400801","volume":"11","author":"C Voena","year":"1997","unstructured":"Voena C, Ladetto M, Astolfi M, Provan D, Gribben JD, Boccadoro M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997;11:1793\u20138.","journal-title":"Leukemia"},{"key":"594_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","volume":"17","author":"VHJ Velden van der","year":"2003","unstructured":"van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013\u201334.","journal-title":"Leukemia"},{"key":"594_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJM199111283252201","volume":"325","author":"JG Gribben","year":"1991","unstructured":"Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525\u201333.","journal-title":"N Engl J Med"},{"key":"594_CR13","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","volume":"78","author":"JG Gribben","year":"1991","unstructured":"Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, et al. All advanced stage non-Hodgkin\u2019s lymphomas with a polymerase chain reaction amplifiable breakpoint of Bcl-2 have residual cells containing the Bcl-2 rearrangement at evaluation and after treatment. Blood. 1991;78:3275\u201380.","journal-title":"Blood"},{"key":"594_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","volume":"13","author":"JR Brown","year":"2007","unstructured":"Brown JR, Yang F, Gribben JG, Nueberg D, Fisher DC, Mauch P, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007;13:1057\u201365.","journal-title":"Biol Blood Marrow Transplant"},{"key":"594_CR15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.V99.3.856","volume":"99","author":"A Rambaldi","year":"2002","unstructured":"Rambaldi A. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856\u201362.","journal-title":"Blood"},{"key":"594_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2008.07101.x","volume":"141","author":"C Hirt","year":"2008","unstructured":"Hirt C, Sch\u00fcler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141:631\u201340.","journal-title":"Br J Haematol"},{"key":"594_CR17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460\u20138.","journal-title":"J Clin Oncol"},{"key":"594_CR18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2002-02-0621","volume":"100","author":"M Ladetto","year":"2002","unstructured":"Ladetto M. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood. 2002;100:1559\u201365.","journal-title":"Blood"},{"key":"594_CR19","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/sj.leu.2404346","volume":"20","author":"M Ladetto","year":"2006","unstructured":"Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, et al. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia. 2006;20:1840\u20137.","journal-title":"Leukemia"},{"key":"594_CR20","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004\u201313.","journal-title":"Blood"},{"key":"594_CR21","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1200\/JCO.2009.22.6258","volume":"27","author":"L Goff","year":"2009","unstructured":"Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, et al. Quantitative PCR analysis for Bcl-2\/IgH in a phase III study of Yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol. 2009;27:6094\u2013100.","journal-title":"J Clin Oncol"},{"key":"594_CR22","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","volume":"122","author":"M Ladetto","year":"2013","unstructured":"\u2022 Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122:3759\u201366 MRD was the most powerful and independent predictor of outcome in a phase III prospective trial.. Accumulation of MRD negative values increased the predictive value.","journal-title":"Blood"},{"key":"594_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","volume":"126","author":"F Zohren","year":"2015","unstructured":"Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, et al. Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 2015;126:1407\u201314.","journal-title":"Blood"},{"key":"594_CR24","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","volume":"20","author":"S Galimberti","year":"2014","unstructured":"Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014;20:6398\u2013405.","journal-title":"Clin Cancer Res"},{"key":"594_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"594_CR26","doi-asserted-by":"crossref","unstructured":"Galimberti S, Ciabatti E, Ercolano G, Grassi S, Guerrini F, Cecconi N, et al. The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: an Italian retrospective study. Front Pharmacol. 2017;8.","DOI":"10.3389\/fphar.2017.00413"},{"key":"594_CR27","doi-asserted-by":"crossref","unstructured":"Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, et al. Analysis of minimal residual disease in follicular lymphoma patients in Gadolin, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed\/refractory indolent non-Hodgkin lymphoma. Blood. 2015.","DOI":"10.1182\/blood.V126.23.3978.3978"},{"key":"594_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood-2016-06-718544","volume":"128","author":"C Pott","year":"2016","unstructured":"\u2022 Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128:613 Preliminary data about a prospective phase III trial suggest that G-based regiment induces rapid and more effective tumor cell clearance than R-containing therapy as first line induction immunochemotherapy in FL.","journal-title":"Blood"},{"key":"594_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood.V98.4.940","volume":"98","author":"C Mandigers","year":"2001","unstructured":"Mandigers C, Meijerink J, Mensink E, T\u00f6nnissen E, Hebeda K, Bogman M, et al. Lack of correlation between numbers of circulating t(14;18)- positive cells and response to first-line treatment in follicular lymphoma. Blood. 2001;98:940\u20134.","journal-title":"Blood"},{"key":"594_CR30","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.leukres.2006.01.014","volume":"30","author":"C Schmitt","year":"2006","unstructured":"Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, et al. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2\/ IgH positive cells: is the end of molecular monitoring near? Leuk Res. 2006;30:1563\u20138.","journal-title":"Leuk Res"},{"key":"594_CR31","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.2009.25.0852","volume":"28","author":"M Oers van","year":"2010","unstructured":"van Oers M, T\u00f6nnissen E, Van Glabbeke M, Giurgea L, Jansen J, Klasa R, et al. BCL-2\/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed\/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010;28:2246\u201352.","journal-title":"J Clin Oncol"},{"key":"594_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-62703-269-8_10","volume":"971","author":"C Pott","year":"2013","unstructured":"Pott C, Br\u00fcggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol. 2013;971:175\u2013200.","journal-title":"Methods Mol Biol"},{"key":"594_CR33","doi-asserted-by":"crossref","unstructured":"Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, et al. Detection by polymerase chain reaction of residual cells with the Bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplant for B-cell lymphoma, n.d., 1993 by The American Society of Hematology edition.","DOI":"10.1182\/blood.V81.12.3449.3449"},{"key":"594_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0301-472X(00)00651-2","volume":"29","author":"M Ladetto","year":"2001","unstructured":"Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, et al. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol. 2001;29:183\u201393.","journal-title":"Exp Hematol"},{"key":"594_CR35","doi-asserted-by":"crossref","unstructured":"Ladetto M, Mantoan B, De Marco F, Drandi D, Aguzzi C, Astolfi M, et al. Cells carrying nonlymphoma-associated bcl-2\/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. Exp Hematol. 34(12):1680\u20136.","DOI":"10.1016\/j.exphem.2006.08.008"},{"key":"594_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrc.2017.127","volume":"18","author":"S Huet","year":"2018","unstructured":"Huet S, Sujobert P, Salles G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat Rev Cancer. 2018;18:224\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"594_CR37","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1200\/JCO.2013.52.8190","volume":"32","author":"S Roulland","year":"2014","unstructured":"Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32(13):1347\u201355.","journal-title":"J Clin Oncol"},{"key":"594_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","volume":"17","author":"D Drandi","year":"2015","unstructured":"Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, et al. Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma. J Mol Diagn. 2015;17:652\u201360.","journal-title":"J Mol Diagn"},{"issue":"4","key":"594_CR39","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.14616","volume":"177","author":"M Cavalli","year":"2017","unstructured":"Cavalli M, De Novi LA, Della Starza I, Cappelli LV, Nunes V, Pulsoni A, et al. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2\/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. Br J Haematol. 2017;177(4):588\u201396.","journal-title":"Br J Haematol"},{"key":"594_CR40","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","volume":"103","author":"D Drandi","year":"2018","unstructured":"Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jim\u00e9nez C, Guerrini F, et al. Highly sensitive MYD88 L265P mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m Macroglobulinemia. Haematologica. 2018;103:1029\u201337.","journal-title":"Haematologica"},{"key":"594_CR41","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood-2017-07-737353","volume":"130","author":"C Pott","year":"2017","unstructured":"Pott C, Knecht H, Herzog A, Genuardi E, Unterhalt M, Mantoan B, et al. Standardized IGH-based next-generation sequencing for MRD detection in follicular lymphoma. ASH annual meeting abstracts. Blood. 2017;130:1491.","journal-title":"Blood"},{"issue":"6","key":"594_CR42","first-page":"1299","volume":"28","author":"M Ladetto","year":"2012","unstructured":"\u2022 Ladetto M, Bruggemann M, Ferrero S, Pepin F, Drandi D, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014. 2012a;28(6):1299\u2013307 A straightforward comparison between PCR-based and NGS based methodologies.","journal-title":"Leukemia 2014"},{"key":"594_CR43","first-page":"2742","volume":"130","author":"E Genuardi","year":"2017","unstructured":"Genuardi E, Klous P, Drandi D, Mantoan B, Monitillo L, Daniela B, et al. Targeted locus amplification (TLA): a novel next generation sequencing (NGS) technology to detect new molecular markers and monitoring minimal residual disease (MRD) in mantle cell and follicular lymphoma. Blood. 2017;130:2742.","journal-title":"Blood"},{"issue":"9","key":"594_CR44","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"P Steven","year":"2012","unstructured":"Steven P, Treon XL, Yang G, Zhou Y, Cao Y, Sheehy P, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia. N Engl J Med. 2012;367(9):826\u201333.","journal-title":"N Engl J Med"},{"issue":"11","key":"594_CR45","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","volume":"121","author":"L Xu","year":"2013","unstructured":"Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstrom Macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051\u20138.","journal-title":"Blood"},{"key":"594_CR46","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1038\/bcj.2014.4","volume":"4","author":"SM Ansell","year":"2014","unstructured":"Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, et al. Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma. Blood Cancer J. 2014;4:e183.","journal-title":"Blood Cancer J"},{"key":"594_CR47","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","volume":"121","author":"M Varettoni","year":"2013","unstructured":"Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s Macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121:2522\u20138.","journal-title":"Blood"},{"key":"594_CR48","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/leu.2013.62","volume":"27","author":"C Jim\u00e9nez","year":"2013","unstructured":"Jim\u00e9nez C, Sebasti\u00e1n E, Chill\u00f3n MC, Giraldo P, Mariano Hern\u00e1ndez J, Escalante F, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\u00f6m\u2019s Macroglobulinemia. Leukemia. 2013;27:1722\u20138.","journal-title":"Leukemia"},{"key":"594_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115\u20139.","journal-title":"Nature"},{"key":"594_CR50","doi-asserted-by":"crossref","unstructured":"Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367:2255\u20136 author reply 2256-2257.","DOI":"10.1056\/NEJMc1211959"},{"key":"594_CR51","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","volume":"102","author":"M Varettoni","year":"2017","unstructured":"Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenstr\u00f6m Macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102:2077\u201385.","journal-title":"Haematologica"},{"key":"594_CR52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","volume":"124","author":"SP Treon","year":"2014","unstructured":"Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom\u2019s macroglobulinemia. Blood. 2014;124:503\u201310.","journal-title":"Blood"},{"key":"594_CR53","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","volume":"127","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127:2072\u201381.","journal-title":"Blood"},{"key":"594_CR54","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","volume":"36","author":"S Luminari","year":"2018","unstructured":"\u2022 Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018;36:689\u201396 With the aim to maximize treatment activity and increase the chance of durable disease control, R-CHOP should be the preferred option among the other options R-CVP and R-FM.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-018-0594-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T19:22:26Z","timestamp":1572981746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-018-0594-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s11864-018-0594-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"6 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Daniele Grimaldi declares that he has no conflict of interest.Elisa Genuardi declares that she has no conflict of interest.Martina Ferrante declares that she has no conflict of interest.Simone Ferrero has received compensation from Janssen for service as a consultant; compensation from Janssen and Pfizer for participation on advisory boards; and compensation from Janssen, Pfizer, and Gilead for service on speakers\u2019 bureaus.Marco Ladetto declares, in the past 5\u00a0years, the following relationships in terms of consultancy, participation on advisory boards, invitations to scientific meetings, institutional research support, and contracts: AbbVie, Acerta, Amgen, Archigen, Celgene, ADC Therapeutics, Gilead, Novartis, Johnson & Johnson, Roche, Roche Diagnostics, Sandoz, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"71"}}